Frontiers in Immunology (Mar 2021)

Complement Overactivation and Consumption Predicts In-Hospital Mortality in SARS-CoV-2 Infection

  • György Sinkovits,
  • Blanka Mező,
  • Blanka Mező,
  • Marienn Réti,
  • Veronika Müller,
  • Zsolt Iványi,
  • János Gál,
  • László Gopcsa,
  • Péter Reményi,
  • Beáta Szathmáry,
  • Botond Lakatos,
  • János Szlávik,
  • Ilona Bobek,
  • Zita Z. Prohászka,
  • Zsolt Förhécz,
  • Dorottya Csuka,
  • Lisa Hurler,
  • Erika Kajdácsi,
  • László Cervenak,
  • Petra Kiszel,
  • Tamás Masszi,
  • István Vályi-Nagy,
  • István Vályi-Nagy,
  • Zoltán Prohászka,
  • Zoltán Prohászka

DOI
https://doi.org/10.3389/fimmu.2021.663187
Journal volume & issue
Vol. 12

Abstract

Read online

ObjectivesUncontrolled thromboinflammation plays an important role in the pathogenesis of coronavirus disease (COVID-19) caused by SARS-CoV-2 virus. Complement was implicated as key contributor to this process, therefore we hypothesized that markers of the complement profile, indicative for the activation state of the system, may be related to the severity and mortality of COVID-19.MethodsIn this prospective cohort study samples of 102 hospitalized and 26 outpatients with PCR-confirmed COVID-19 were analyzed. Primary outcome was in-hospital, COVID-19 related mortality, and secondary outcome was COVID-19 severity as assessed by the WHO ordinal scale. Complement activity of alternative and classical pathways, its factors, regulators, and activation products were measured by hemolytic titration, turbidimetry, or enzyme-immunoassays. Clinical covariates and markers of inflammation were extracted from hospital records.ResultsIncreased complement activation was characteristic for hospitalized COVID-19 patients. Complement activation was significantly associated with markers of inflammation, such as interleukin-6, C-reactive protein, and ferritin. Twenty-five patients died during hospital stay due to COVID-19 related illness. Patients with uncontrolled complement activation leading to consumption of C3 and decrease of complement activity were more likely to die, than those who had complement activation without consumption. Cox models identified anaphylatoxin C3a, and C3 overactivation and consumption (ratio of C3a/C3) as predictors of in-hospital mortality [HR of 3.63 (1.55–8.45, 95% CI) and 6.1 (2.1–17.8), respectively].ConclusionIncreased complement activation is associated with advanced disease severity of COVID-19. Patients with SARS-CoV-2 infection are more likely to die when the disease is accompanied by overactivation and consumption of C3. These results may provide observational evidence and further support to studies on complement inhibitory drugs for the treatment of COVID-19.

Keywords